Adelaide Research & Scholarship: Search

Search

Results 1-10 of 53 (Search time: 0.004 seconds).

previous
1
2
3
4
...
6
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2016	ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatment	Eadie, L.; Hughes, T.; White, D.; New Directions in Leukaemia Research 2016 Meeting (NDLR) (16 Mar 2016 - 19 Mar 2016 : Noosa, QLD)
	2013	STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner	Schafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; White, D.; Hughes, T.; Leclercq, T.
	2010	Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial	Yeung, D.; Osborn, M.; White, D.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Forsyth, C.; Ross, D.; Mills, A.; Grigg, A.; Hughes, T.; Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
	1995	A direct analysis of FACS-sorted hemopoietic cell fractions using fish	White, D.; Hutchins, C.; Haylock, D.; Turczynowics, S.; Bishop, A.; To, L.; Hughes, T.; Juttner, C.
	2000	Normal and leukemic engraftment in the nod/scid mouse model	Hughes, T.; White, D.; Bresatz, S.; Forte, M.; Lewis, I.; Lyons, A.
	2017	Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia	Sopper, S.; Mustjoki, S.; White, D.; Hughes, T.; Valent, P.; Burchert, A.; Gjertsen, B.; Gastl, G.; Baldauf, M.; Trajanoski, Z.; Giles, F.; Hochhaus, A.; Ernst, T.; Schenk, T.; Janssen, J.; Ossenkoppele, G.; Porkka, K.; Wolf, D.
	2018	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells	Ross, D.; Pagani, I.; Shanmuganathan, N.; Kok, C.; Seymour, J.; Mills, A.; Filshie, R.; Arthur, C.; Dang, P.; Saunders, V.; Braley, J.; Yong, A.; Yeung, D.; White, D.; Grigg, A.; Schwarer, A.; Branford, S.; Hughes, T.
	2016	TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy	Nievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Fuller, K.; Erber, W.; Sadras, T.; Grose, R.; Yeung, D.; Lopez, A.; Hiwase, D.; Hughes, T.; White, D.
	2015	KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy	Yeung, D.; Tang, C.; Vidovic, L.; White, D.; Branford, S.; Hughes, T.; Yong, A.
	2012	Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells	Wang, J.; Hughes, T.; Kok, C.; Saunders, V.; Frede, A.; Groot Obbink, K.; Osborn, M.; Somogyi, A.; D'Andrea, R.; White, D.